AllianceBernstein
MLNT

AllianceBernstein’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

AllianceBernstein’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-8,668
Closed -$34K – 3148
2018
Q4 		$34K Hold
8,668
– – ﹤0.01% 3073
2018
Q3 		$171K Buy
8,668
+820
+10% +$20.7K ﹤0.01% 3009
2018
Q2 		$249K Buy
7,848
+3,880
+98% +$140K ﹤0.01% 2881
2018
Q1 		$147K Buy
3,968
+420
+12% +$27.6K ﹤0.01% 2922
2017
Q4 		$280K Buy
+3,548
New +$263K ﹤0.01% 2736

Other funds holding MLNT

IP
Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's MLNT Position: Q1 2019 in Review

AllianceBernstein sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 8,668 shares — an estimated $34K sold.

AllianceBernstein first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $280K in Q4 2017. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

  • AllianceBernstein reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • AllianceBernstein sold 8,668 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $34K.
  • AllianceBernstein first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
  • AllianceBernstein's Melinta Therapeutics, Inc. Common Stock position peaked at $280K in Q4 2017.
  • 52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on AllianceBernstein's 13F filing for Q1 2019, filed 14 May 2019.